Skip to main content

Table 1 Comparison of demographic and clinical characteristics between responders and non-responders from VPA arm

From: Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache

 

Responders

Non-responders

 

(N = 18)

(N = 26)

 
 

N

%

N

%

p-value

Sex

     

 F

14

77.8

21

80.8

0.8089

 M

4

22.2

5

19.2

 

Age class (years)

 18-34

2

11.1

3

11.5

0.8259

 35-44

9

50

11

42.3

 

 45-54

4

22.2

9

34.6

 

 55-64

3

16.7

3

11.5

 

BMI class

 (<18) underweight

0

0

1

3.9

0.4251

 (18–24.9) normal weight

8

44.4

16

61.5

 

 (25–29.9) overweight

8

44.4

6

23.1

 

 (>30) obese

2

11.2

3

11.5

 

Comorbidity

 No

17

94.4

20

76.9

0.1182

 Yes

1

5.6

6

23.1

 

Surgery

 No

2

11.8

6

24

0.3216

 Yes

15

88.2

19

76

 

 Missing

1

 

1

  

Headache days/months (V1)

 15-25

12

66.7

14

53.8

0.4405

 >25

6

33.3

12

46.2

 

Headache intensity (V1)

 Slight

0

0

1

3.8

0.6987

 Moderate

6

33.3

8

30.8

 

 Severe

12

66.7

17

65.4

 

Headache days/month (V2)

 15-25

17

94.4

19

73.1

0.1216

 >25

1

5.6

7

26.9

 

Headache intensity (V2)

 Slight

3

16.7

3

11.5

0.7040

 Moderate

11

61.1

19

73.1

 

 Severe

4

22.1

4

15.4

 

Headache duration (years)

 0-10

1

5.6

5

19.2

0.4249

 11-20

6

33.3

7

26.9

 

 21-30

7

38.9

6

23.1

 

 >30

4

22.2

8

30.7

 

 MOH duration (years)

     

 <1

2

11.1

4

15.4

0.5182

 1-3

4

22.2

6

23.1

 

 3-5

7

38.9

5

19.2

 

 >5

5

27.8

11

42.3

 

Overused drugs

 Analgesics >14d

9

50

6

23.1

0.2703

 Analgesics combinations >9d

2

11.1

3

11.5

 

 Drug combinations >9d

2

11.1

7

26.9

 

 Triptan combinations >9d

5

27.8

10

38.5

 
  1. VPA: sodium valproate.
  2. BMI: body mass index.
  3. V1: baseline first visit.
  4. V2: second visit at the start of detoxification.
  5. d: days.